Stockwinners Market Radar for March 14, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:52 EDT Corporacion America Airport reports February passenger traffic up 5.5% - Corporacion America Airports reported preliminary year-over-year passenger traffic growth of 5.5% in February 2019, primarily reflecting growth of 7.9% in Argentina, 2.8% in Brazil and 8.2% in Ecuador. Cargo volume increased 11.8% in February 2019 mainly as a result a 98.5% increase in Brazil, mainly related to an increase in exports, offset by a decline of 7.9% in Argentina, related to the continued challenging macroeconomic conditions. Aircraft movements increased 2.5% in February 2019, mainly as a result of increases of 4.5% in Argentina and 24.0% in Ecuador, partially offset by a 6.4% decline in Brazil.

19:10 EDT Fly Intel: After Hours Movers - UP AFTER EARNINGS: Broadcom (AVGO) up 5.2%... Avid Technology (AVID) up 5.1%... Ulta Beauty (ULTA) up 3.4%... Rise Education (REDU) up 3.3%... Huazhu Group (HTHT) up 2.7%. ALSO HIGHER: Karyopharm Therapeutics (KPTI) up 27.7% after being granted FDA extension of PDUFA date for selinexor NDA. DOWN AFTER EARNINGS: Ascena Retail (ASNA) down 17.5%... Turtle Beach (HEAR) down 12.3%... Ra Medical (RMED) down 8.7%... DocuSign (DOCU) down 7.4%... Zumiez (ZUMZ) down 6.2%... ViewRay (VRAY) down 4.0%... Pivotal Software (PVTL) down 4.0%... Oracle (ORCL) down 3.4%... Papa Murphy's (FRSH) down 3.2%... Adobe (ADBE) down 2.6%. ALSO LOWER: Zillow (ZG) down 3.0% after Barclays downgrade to Underweight... Facebook (FB) down 1.7% after disclosing Chief Product Officer Chris Cox has stepped down. Movers as of 18:45ET.

18:04 EDT EP Energy sees Q1 production 72-73 MBOE/D

17:49 EDT Nanometrics announces $80M share repurchase program - Nanometrics announced that its board of directors has authorized the repurchase of up to $80M of the company's common stock. "Nanometrics' management team and board of directors are confident in the company's future growth prospects and are also committed to returning capital to our stockholders," commented Bruce C. Rhine, chairman of the board of Nanometrics. "We continue to have a strong balance sheet and have generated $96 million in free cash flows over the past year. We believe the company has the financial position to invest for future growth, as well as fund this $80 million stock repurchase program. Following up on the prior $50 million plan, which was completed early in 2018, we believe the stock repurchases will create further value for our stockholders." This $80M program is effective immediately. Share repurchases under this program may be made through open market and privately negotiated transactions, at times and in such amounts as management deems appropriate. As of December 29, Nanometrics had $152M in cash, cash equivalents and marketable securities, and approximately 24.4M shares outstanding.

17:39 EDT Construction Partners 'applauds' Alabama gas tax increase - Construction Partners, Inc. issued a statement following the enactment of the Rebuild Alabama Act earlier this week, which provides for an increase in Alabama's gas tax to be used for transportation infrastructure projects. "We applaud Governor Ivey and the Alabama legislature for working in a bipartisan manner to ensure a stable source of funding for transportation infrastructure projects across the state," said Charles E. Owens, President and Chief Executive Officer of the company. "The additional resources generated by the Rebuild Alabama Act will continue to drive economic development and public safety efforts in the state. We look forward to playing our part in rebuilding Alabama's roads and bridges." The Rebuild Alabama Act provides for a ten-cent increase in Alabama's tax on gasoline and diesel fuel that will be phased in over three years, with an increase of six cents per gallon on October 1, 2019, two cents per gallon on October 1, 2020, and two cents per gallon on October 1, 2021. Beginning in 2023, the tax will be tied to the National Highway Construction Cost Index and will be subject to automatic adjustments of up to one cent every two years. The law, which represents the first increase in Alabama's gas tax since 1992, is expected to generate approximately $320M in additional annual funding for investment in Alabama's roads and bridges when fully implemented.

17:35 EDT Newell Brands CEO Michael Polk to retire at the end of Q2 - Newell Brands announced that Michael Polk, the company's President and Chief Executive Officer since 2011 and a member of the Newell Brands board of directors since 2009, will retire from the company at the end of the second quarter. The board and Polk have agreed that, as the company nears the completion of its Accelerated Transformation Plan, now is the right time for a management transition. The board has commenced a search process to identify the company's next CEO, and has retained Heidrick & Struggles, a leading global executive search firm, to assist in a thorough search process.

17:35 EDT LiveWell finalizes hemp CBD supply agreement with Tilray - LiveWell Canada announced it has finalized its CBD supply agreement with Tilray. LiveWell will supply Tilray with a monthly quantity of up to 300 kilograms of hemp-derived CBD isolate, or an equivalent amount of full-spectrum CBD extract. The Company expects to begin shipping Tilray its product during the second quarter of 2019. "We're thrilled to have the opportunity to partner with Tilray, one of the best known and most stringent companies in the cannabis and cannabinoid space," said David Rendimonti, President and CEO of LiveWell Canada. "As we've previously outlined, one of our key priorities is capturing greater market share in wholesale. The finalization of this milestone agreement is a strong validator of our ability to produce and supply some of the highest-quality hemp-derived CBD available on the market. We look forward to a strong continuing relationship with Tilray." Under the terms of the agreement, LiveWell will initially supply Tilray with up to 150 kilograms per month of wholesale CBD isolate, or an equivalent amount of full-spectrum CBD extract, cultivated and processed from hemp, and meeting jurisdictional regulations. As of August 2019, the amount increases to 300 kilograms per month, with an option to increase to 500 kilograms per month. The Agreement is in effect until January 31, 2020, at which time it will automatically renew for successive 12-month terms unless either party has opted out of such renewal.

17:26 EDT Raytheon awarded $402.66M Navy contract modification for three AMDR LRIP units - Raytheon has been awarded a $402.66M mixed-price-incentive modification to a previously-awarded contract to exercise options for Air and Missile Defense Radar program, or AMDR, low-rate initial production, or LRIP. This modification will provide for three AMDR LRIP units. The LRIP units will be deployed on DDG 51 Flight III-class ships. Work will be performed in Marlborough, Massachusetts and is expected to be completed by March 2023. FY19 shipbuilding and conversion funding in the amount of $402.66M will be obligated at time of award and will not expire at the end of the current fiscal year. The Naval Sea Systems Command is the contracting activity.

17:20 EDT Fox Corp to replace 21st Century Fox on S&P 500 as of 3/19 open - Fox Corp. (FOXAV, FOXBV) will be added to the S&P 500 prior to the open of trading on Tuesday, March 19. Fox will replace Twenty-First Century Fox Inc. (FOXA,FOX), which will be removed from the S&P 500 and S&P 100 effective prior to the open of trading on Wednesday, March 20. S&P 500 and 100 constituent The Walt Disney Co. (DIS) is acquiring Twenty-First Century Fox one day after Twenty-First Fox spins off Fox Corp. to shareholders.

17:13 EDT Oracle sees FY20 revenue growth 'higher' than FY19

17:10 EDT Health Insurance Innovations expands stock buyback by $100M to $200M - Health Insurance Innovations announced that its board has increased the amount of the authorized repurchase of the company's common stock from $100M up to $200M and extended the authorization through October 2020. Through March 14, 2019, the company has repurchased an aggregate of approximately $77.3M in shares under the previous authorization.

17:04 EDT Karyopharm announces FDA extension of PDUFA date for selinexor NDA - Karyopharm announced that the FDA has extended the Prescription Drug User Fee Act, or PDUFA, action date for the new drug application, or NDA for selinexor. The NDA, which is currently under priority review by the FDA, is seeking accelerated approval for selinexor in combination with dexamethasone for the treatment of patients with relapsed refractory multiple myeloma who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor, or PI, one immunomodulatory agent, or IMiD and one anti-CD38 monoclonal antibody. The previously disclosed April 6 PDUFA date has been extended by three months to July 6. On February 26, the FDA's Oncologic Drugs Advisory Committee, or ODAC, met to discuss the selinexor NDA and voted 8 to 5 recommending that the FDA wait for the results from Karyopharm's randomized, open-label, Phase 3 BOSTON study evaluating selinexor in patients with relapsed or refractory multiple myeloma, before making a final decision regarding approval. Although the FDA considers the recommendation of this panel, the final decision regarding the approval of the product is made by the FDA solely, and the recommendations by the panel are non-binding. Following the ODAC meeting, at the FDA's request, Karyopharm submitted additional, existing clinical information as an amendment to the NDA, which allowed the FDA to extend the PDUFA action date by three months.

16:59 EDT FDA accepts Adamis' NDA of higher dose naloxone injection product candidate - Adamis Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted for review the company's New Drug Application for its higher naloxone injection product candidate for the treatment of opioid overdose. On March 14, 2019, Adamis received FDA correspondence relating to the company's NDA stating that the Agency had completed its filing review and had determined that the NDA was sufficiently complete to permit a substantive review. The FDA further provided a target agency action date of October 31.

16:47 EDT Chipotle announces new members Patricia Fili-Krushel and Scott Maw to board - Chipotle Mexican Grill announced the addition of two new members to its board of directors, effective immediately: Patricia Fili-Krushel and Scott Maw. The new directors will serve an initial term through Chipotle's 2019 annual meeting of shareholders in May. "As we continue to evolve our brand and grow the business, it is an honor to welcome Pat and Scott to our board of directors," said Brian Niccol, Chief Executive Officer of Chipotle. "From contributions in global business strategy and talent management, to finance and risk management, I'm confident both Pat's and Scott's perspectives and valuable insights will help us accelerate our goals." In addition to the new board members, one of Chipotle's current directors, Kimbal Musk, notified the Board that he has decided to not stand for re-election at the 2019 annual meeting of shareholders. "Kimbal has served on the Chipotle Board of Directors since 2013, and we extend our most sincere gratitude and heartfelt appreciation for the tremendous contributions he has made to our success," said Niccol. "We value his time, leadership and experience and wish him all the very best."

16:42 EDT Adobe says photography business continues to show strong momentum - Says Lightroom CC mobile subscribers has increased by more than 400% over the past year. Says addition of Allegorithmic further expands Creative Cloud into interactive content design and allows the company to better equip video game creators, visual FX artists, designers and marketers. Says approximately 91% of revenue in Q1 was from recurring sources. Comments taken from Q1 earnings presentation.

16:35 EDT Ascena Retail trading resumes

16:30 EDT Colgate-Palmolive raises quarterly dividend to 43c per share from 42c - The board of directors of Colgate-Palmolive Company increased the quarterly common stock cash dividend to 43c per share, up from 42c per share. The increase will be effective in the second quarter, 2019. The board declared that the second quarter dividend is to be paid on May 15, 2019 to shareholders of record as of April 19, 2019. On an annualized basis, the new dividend rate is $1.72 versus $1.68 per share previously.

16:29 EDT DocuSign down 10% to $52.86 after Q4 results, FY20 guidance

16:28 EDT Fuel Tech awarded air pollution control orders totaling $3M - Fuel Tech announced the receipt of multiple air pollution control contracts from customers in the US, Europe and China, all for projects located in China. These awards have an aggregate value of approximately $3M. An order from Europe was received for ULTRA systems that will be installed on multiple industrial units firing municipal solid waste and being retrofitted with Selective Catalytic Reduction technology. Fuel Tech's ULTRA process provides for the safe and cost-effective on-site conversion of urea to ammonia for use as a reagent where SCR is used to reduce nitrogen oxide, eliminating the hazards associated with the transport, storage and handling of anhydrous or aqueous ammonia. Delivery of these systems will be completed in the first quarter of 2020. Two US contracts were received for multiple NOxOUT Selective Non-Catalytic Reduction systems for two industrial plants firing natural gas. Fuel Tech's SNCR technology is a proven solution as industrial combustion unit owners look to comply with more stringent NOx control requirements. Deliveries for these systems will be completed by the third quarter of 2019. Two additional SNCR orders were received for a utility coal-fired boiler and an industrial unit burning hazardous waste, with deliveries to be completed by the first quarter of 2019.

16:23 EDT Broadcom reports Q1 adj. cont ops gross margin 71.4% vs. 64.8% a year ago

16:21 EDT Broadcom reports Q1 gross margin 55.4% vs. 49.3% a year ago

16:21 EDT U.S. Silica receives SandBox Logistics patent confimation from USPTO - U.S. Silica announced that the USPTO has confirmed several additional patent claims covering fundamental aspects of technology owned by its SandBox Logistics business unit. These wins mean that Proppant Express Investments is judicially barred from making the same or similar invalidity arguments in any future infringement proceedings involving these patents.

16:19 EDT Everspin Technologies names Troy Winslow as VP of Global Sales - Everspin Technologies (MRAM) announced that Troy Winslow will be joining the company as the Vice President of Global Sales starting March 18, 2019. Winslow was Vice President of Worldwide System Sales for Microsemi, a subsidiary of Microchip Technologies (MCHP).

16:18 EDT SAIC wins $57M Seaport-e task order - Science Applications International Corp. won a $57MSeaport-e task order to provide engineering support services to the Polymers and Undersea Sensors Branch at the Naval Surface Warfare Center, Crane Division. "This win not only continues the strong partnership we've had for 30 years with NSWC Crane," said Jim Scanlon, executive vice president and general manager of SAIC's Defense Systems customer group, "but it is also an affirmation of the Product Support Center services model we've developed with them." On this contract, SAIC will also deliver research and development services, rapid prototype development, test and evaluation and depot overhaul and repair for various sensors, underwater cables and specialty molded elastomer products throughout the Fleet. The task order has a one-year base period of performance with four additional option years.

16:17 EDT Xeris Pharmaceuticals doses first patient in Phase 2 EIH trial - Xeris Pharmaceuticals announced that it has now begun dosing patients in a Phase 2 trial with its ready-to-use, room-temperature stable liquid glucagon in patients with Type 1 diabetes who experience episodes of exercise-induced hypoglycemia. "Many individuals with diabetes treated with insulin experience EIH and the complexity of managing it is a major barrier to the adoption of regular physical activity. And unfortunately, today there are no approved therapies to prevent EIH. This research will help us understand the potential for ready-to-use glucagon to offer real-world benefit in reducing or preventing these challenging events during exercise," said Dr. Ronnie Aronson, MD, FRCPC, FACE, endocrinologist and chief medical officer of LMC Diabetes & Endocrinology, Toronto, Canada. Dr. Aronson is the principal investigator on the EIH trial.

16:16 EDT Mercury Systems receives $3M rugged server order - Mercury Systems announced it received a $3M order from a leading defense prime contractor for rugged servers to be used in an Army communications application. The order was booked in Q3.

16:14 EDT Cubic acquires Nuvotronics for approximately $64M in cash - Cubic announced the acquisition of Nuvotronics, a disruptive technology provider of microfabricated radio frequency products, for approximately $64M in cash, subject to customary adjustments, with additional earn-out payments of up to $8M based on future performance. With the acquisition of Nuvotronics, Cubic expects to accelerate multiple innovation initiatives across Cubic's protected communications portfolio and beyond, and to capture significant supply chain synergies, which are expected to enhance EBITDA beginning fiscal year 2020. Cubic anticipates the transaction to be accretive to cash earnings per share by the second full year of operations. Cubic financed the acquisition from its existing credit facility.

16:12 EDT DocuSign sees FY20 adjusted gross margin 78%-80%

16:11 EDT Zumiez reports February SSS down 3.8%

16:05 EDT Oracle raises quarterly dividend 26% to 24c from 19c per share - This increased dividend will be paid to stockholders of record as of the close of business on April 11, with a payment date of April 25.

16:04 EDT Oracle CEO Catz says 'our overall operating margin improved to 44%' - "I'm pleased with Q3 non-GAAP results as revenues grew 3%, operating income increased 5% and EPS grew 12% in constant currency," said Oracle CEO, Safra Catz. "Our overall operating margin improved to 44% as our lower margin hardware business continued to get smaller while our higher margin cloud business continued to get bigger. With year-to-date non-GAAP EPS growth rate now at 16% in constant currency, we will comfortably deliver another year of double-digit EPS growth." "Our Fusion HCM, ERP, Supply Chain and Manufacturing Cloud applications revenue in total grew 32% in Q3," said Oracle CEO, Mark Hurd. "Our NetSuite ERP Cloud applications also delivered strong results with a revenue growth rate of 30%. That said, let me call your attention to the following approved statement about Oracle's entire applications business from industry analyst IDC."

16:04 EDT Oracle reports Q3 short-term deferred revenue $8B, up 1% - Short-term deferred revenues were up 1% to $8B compared to a year ago. Operating Cash Flow was $14.8B during the trailing twelve months.

16:01 EDT Esterline trading resumes

16:00 EDT L B Foster trading halted, news pending

15:22 EDT President Trump tweets 'VETO!' - U.S. President Donald Trump tweeted the word "VETO!" this afternoon. The Tweet follows a report from the Washington Post saying that a group of Senate Republicans have joined with Senate Democrats to "approve a disapproval resolution aimed at overturning President Trump's declaration of an emergency on the U.S.-Mexico border." Reference Link

15:16 EDT Harel Insurance reports 5% passive stake in Partner Communications - In a regulatory filing, Harel Insurance disclosed a 5% stake in Partner Communications, which represents roughly 8.22M shares. The filing does not allow for activism.

14:38 EDT DPW Holdings announces one-for-twenty reverse stock split - DPW Holdings, Inc. announced that its board of directors has approved a one-for-twenty reverse stock split of its Class A common stock that will be effective in the State of Delaware on March 14, 2019. Beginning with the opening of trading on March 15, 2019, the company's Common Stock will trade on the NYSE American on a split-adjusted basis under a new CUSIP number, 26140E 501. At the company's Special Meeting of Stockholders held at 12:00 pm Eastern Time today, the company's stockholders approved a proposal authorizing the company's board of directors to effect a reverse stock split by a whole number ratio of not less than one-for-four and not more than one-for-twenty at any time prior to March 14, 2020, with the exact ratio to be set at a whole number within this range as determined by the board of directors in its sole discretion. The company reported that 72,253,978 favorable votes were cast, representing nearly 64.0% of the company's outstanding shares eligible to vote as of the record date. Subsequently, upon approval by the board of directors, the company filed a certificate of amendment to the company's Certificate of Incorporation, effectuating the one-for-twenty reverse stock split, with the Secretary of State of the State of Delaware on March 14, 2019. The reverse stock split affects all issued and outstanding shares of the company's Common Stock, as well as the number of shares of Common Stock available for issuance under the company's equity incentive plans. In addition, the reverse stock split reduces the number of shares of Common Stock issuable upon the exercise of stock options or warrants outstanding immediately prior to the reverse split. The par value of the company's Common Stock will remain unchanged at $0.001 per share after the reverse stock split. The reverse stock split affects all stockholders uniformly and will not alter any stockholder's percentage interest in the company's equity, except to the extent that the reverse stock split results in some stockholders owning a fractional share as described below. The reverse stock split will reduce the number of shares of Common Stock issued and outstanding from approximately 125,080,765 to approximately 6,254,038. The authorized number of shares of Common Stock will remain at 500 million.

14:04 EDT Bayer reports Phase 3 trial of nifurtimox meets primary endpoint - Bayer presented results from the CHICO part of the phase 3 clinical study of investigational nifurtimox in pediatric patients with Chagas disease at the "XV Taller sobre la enfermedad de Chagas" conference in Barcelona, Spain. The study met its primary endpoint, which was the serological response at one year after end of treatment, by demonstrating superiority of the 60-day nifurtimox treatment compared with historical placebo control. Safety and efficacy were evaluated throughout the clinical trial. CHICO was the first part of a prospective, randomized, double-blind, historically placebo controlled phase 3 trial to evaluate the efficacy, safety, and pharmacokinetics of nifurtimox in 330 pediatric patients with acute or chronic Chagas disease. The study was conducted at 25 investigational sites in Argentina, Bolivia and Colombia between 2016 and 2018.

13:58 EDT Abbott confirms FDA approval for expanded MitraClip indication - Abbott announced it received approval from the U.S. Food and Drug Administration for a new, expanded indication to its MitraClip device used to repair a leaky mitral valve without open-heart surgery. "MitraClip is the first transcatheter mitral valve intervention therapy approved to treat select heart failure patients with clinically significant secondary, or functional, mitral regurgitation...The new, expanded indication addresses the secondary form of MR and significantly increases the amount of people with MR able to be treated with MitraClip. Based on this approval, Abbott will begin discussions with the Center for Medicare and Medicaid Services and physician specialty societies to request a revision to the national coverage determination that would expand Medicare coverage to include secondary MR patients," the company stated.

13:36 EDT Blue Capital trading halted, news pending

13:06 EDT Millicom sells operations in Chad to Maroc Telecom - Millicom announced that it has signed an agreement for the sale of its entire operations in Chad to Maroc Telecom. The completion of the transaction is subject to the approval of the Chadian authorities. The sale of Tigo Chad is in line with Millicom's stated objective of increasing its focus on Latin America, the company said. The transaction is not expected to have a material impact on the company as a whole, it added.

12:22 EDT Alvogen request for IPR review of Celgene patent denied by USPTO - The U.S. Patent and Trademark Office stated in a notice posted to its site that Alvogen Pine Brook filed a Petition requesting institution of an inter partes review of claims 1-15 of U.S. Patent No. 7,968,569 held by Celgene. The '569 patent describes a combination cancer therapy that encompasses administering an immunomodulatory compound1 with one or more other therapeutically active agents to a patient having "relapsed multiple myeloma," a type of blood cancer. Alvogen's application does not meet the threshold of "a reasonable likelihood that the petitioner would prevail with respect to at least 1 of the claims challenged in the petition," according to the USPTO, which denied the petition and did not institute an inter partes review, according to the notice.

12:13 EDT Microsoft announces Game Stack for developers - In a blog post, Microsoft announced a new initiative, Microsoft Game Stack, in which it aims to bring together Microsoft tools and services that will "empower game developers," from indie devs just starting out or a AAA sutdio, to "achieve more." The company said that Game Stack brings together all of Microsoft's game-development platforms, tools, and services-such as Azure, PlayFab, DirectX, Visual Studio, Xbox Live, App Center, and Havok-into a robust ecosystem that any game developer can use. The goal of Game Stack is to help developers easily discover the tools and services needed to create and operate their games. "As we expand our focus to the cloud, the nature of the platform may be changing, but our commitment to empower game developers like yourself is unwavering, and we're looking forward to the journey ahead with Microsoft Game Stack," Microsoft's Kareem Choudhry said. "Our teams are inspired and excited by the possibilities as we start to pull together all these great services and technologies. Please be sure to share your feedback with us as we go, so we can help you achieve more. If you're at GDC, stop by the Microsoft booth in the South Hall of the Moscone Center to try out many of the new services, and to learn more about the exciting opportunities ahead." Reference Link

12:01 EDT Lakeland Financial appoints Brok Lahrman Chief Accounting Officer - Lakeland Financial announced that Brok Lahrman has joined the bank as senior VP of Finance and Chief Accounting Officer. Lahrman is a former Senior Manager at BKD, LLP in Fort Wayne, Indiana.

12:00 EDT Tailored Brands falls -23.7% - Tailored Brands is down -23.7%, or -$2.77 to $8.91.

12:00 EDT Farmland Partners rises 11.2% - Farmland Partners is up 11.2%, or 60c to $5.98.

12:00 EDT WageWorks rises 29.1% - WageWorks is up 29.1%, or $8.68 to $38.55.

11:46 EDT MongoDB CEO says company partners and competes with Amazon - MongoDB (MDB) CEO Dev Ittycheria, during an interview on CNBC, said that his company both partners with and competes with Amazon (AMZN), adding "Who doesn't compete with Amazon today?".

11:34 EDT Bridgeline Digital acquires OrchestraCMS assets from Stantive Technologies Group - Bridgeline Digital (BLIN) announced their acquisition of certain assets of Stantive Technologies Group including OrchestraCMS, the leading digital experience platform built 100% native on Salesforce.com (CRM). The OrchestraCMS platform helps Salesforce (CRM) customers create employee intranets, customer portals and marketing Web sites. The native integration with Salesforce enables the platform to access the underlying infrastructure of the CRM, including security model, data, apps, workflow and other processes to deliver online experiences across any channel or device.

11:07 EDT Toyota to produce RAV4, Lexus ES hybrid versions in Kentucky - A state-by-state look at the new investments totaling $749M and 586 new jobs: Toyota Motor Manufacturing, Alabama- $288,000,000. In Alabama, Toyota's investment will increase annual engine capacity from 670,000 to 900,000 by the end of 2021 to increase product flexibility and better accommodate market demand. New 4-cylinder and V6 engine lines will add 450 new jobs to its Huntsville, Alabama, facility, the largest hiring need in the plant's history. The investment also includes a building expansion. Overall, the plant represents an investment of $1.2B. Toyota Motor Manufacturing, Kentucky - $238,000,000: Toyota's Kentucky vehicle plant, the company's largest globally, will begin production of the Lexus ES 300h hybrid in May 2019 with annual capacity of 12,000 units while RAV4 Hybrid production will start January 2020 with an annual capacity of 100,000 units. TMMK's 8,000 team members also build Camry, Camry Hybrid, Avalon, Avalon Hybrid and Lexus ES models with an annual capacity of 550,000 vehicles. Overall, the plant represents an investment of more than $7B. Bodine Aluminum Troy, Missouri - $62,000,000: Investments in Toyota's Bodine Aluminum plant in Missouri will provide equipment to produce an additional 864,000 cylinder heads for Toyota's New Global Architecture. Bodine's 900 Missouri team members currently produce more than 3 million cylinder heads a year, which are made for every Toyota and Lexus manufactured in North America. Overall, the plant represents an investment of $455M. Bodine Aluminum Jackson, Tennessee - $50,000,000: The Tennessee investment includes a building expansion and equipment to double the capacity of hybrid transaxle cases and housings to 240,000 annually. The investment will also provide equipment to produce an additional 288,000 engine blocks a year for TNGA. The plant's 300 team members currently produce 1.7 million engine blocks a year, which supply every Toyota and Lexus manufactured in North America, and 580,000 transmission cases and housings. Bodine will add 13 new jobs to its facility in Tennessee. Overall, the plant represents an investment of $365M. Toyota Motor Manufacturing, West Virginia - $111,000,000: The West Virginia investment includes a building expansion and equipment to double capacity of hybrid transaxles from 120,000 units to 240,000 units annually in 2021. To meet the production demands, TMMWV will add 123 new jobs to its facility in Buffalo, West Virginia. Overall, the plant represents a $1.4B investment.

11:03 EDT FDA approves new indication for Abbott's MitraClip - The U.S. Food and Drug Administration approved a new indication for a heart valve repair device that is intended to reduce moderate-to-severe or severe mitral regurgitation, a leakage of blood backward through the mitral valve into the heart's left atrium that can cause heart failure symptoms such as shortness of breath, fatigue and swelling in the legs. When first approved in 2013, the MitraClip Clip Delivery System was indicated to reduce mitral regurgitation in certain patients whose significant mitral regurgitation and heart failure symptoms result from abnormalities of the mitral valve and whose risks for mitral valve surgery are prohibitive. The new indication, approved today, is for treatment of patients with normal mitral valves who develop heart failure symptoms and moderate-to-severe or severe mitral regurgitation because of diminished left heart function despite being treated with optimal medical therapy. The MitraClip Clip Delivery System is manufactured by Abbott Vascular.

10:19 EDT CIT Group names James Hubbard as general counsel - CIT Group announced that James Hubbard has been named the company's general counsel and corporate secretary, effective March 18, 2019. Hubbard will join CIT's Executive Management Committee and report to Chairwoman and CEO Ellen Alemany. Hubbard will have oversight over the legal function and all outside counsel relationships, as well as responsibility for all business and corporate legal matters. Hubbard joins CIT from TIAA Bank where he was the general counsel and secretary.

10:03 EDT Boxlight acquires Modern Robotics, terms not disclosed - Boxlight Corporation announced it has completed the acquisition of Modern Robotics, a STEM education company with programming and robotics solutions for the K-12 education market. Modern Robotics are the developers of MyBot, e K-12 ecosystem and robotics program that helps students from pre-school to high school develop skills for programming and robotics. Through the cohesive software platform and innovative robots, educators receive an out-of-the-box solution, complete with a robust curriculum, STEM lessons, tutorials and videos. The company said, "Over the next 12 months, it's expected that Boxlight will produce over $2M in robotics and programming revenues with gross profit margins greater than 50%. The acquisition also brings significant management talent to Boxlight by adding Modern Robotics' current CEO Stephen Barker, who will fill the role of VP, STEM Education."

10:00 EDT Tailored Brands falls -23.4% - Tailored Brands is down -23.4%, or -$2.74 to $8.95.

10:00 EDT Talos Energy rises 9.5% - Talos Energy is up 9.5%, or $2.17 to $24.92.

10:00 EDT WageWorks rises 26.6% - WageWorks is up 26.6%, or $7.93 to $37.80.

09:47 EDT Cloudera falls -12.5% - Cloudera is down -12.5%, or -$1.83 to $12.78.

09:47 EDT Tailored Brands falls -25.0% - Tailored Brands is down -25.0%, or -$2.92 to $8.77.

09:47 EDT Talos Energy rises 9.2% - Talos Energy is up 9.2%, or $2.09 to $24.84.

09:46 EDT General Electric expects working capital lower in FY19

09:31 EDT General Electric CEO has 'high level' of belief that cash flow will improve

09:29 EDT Kitov Pharmaceuticals to acquire clinical stage candidate CM-24 - Kitov Pharma announced it has signed an agreement to acquire FameWave, a privately held biopharmaceutical company developing CM-24, a clinical stage monoclonal antibody targeting CEACAM1, a novel immune checkpoint. Kitov is planning initiation of a Phase I/II study in early 2020 to evaluate the safety and efficacy of CM-24 in combination with an anti PD-1 inhibitor. Kitov to host a conference call to discuss the transaction. Preclinical studies provide strong justification for CM-24's mechanism of action in activating the immune system through multiple pathways as validated by world renowned researchers at Harvard Medical School and MIT, in an article published in Nature as well as by Prof. Gal Markel from the Tel Hashomer Medical Center. Additional preclinical studies showed that a combination of CM-24 with a PD-1 antibody resulted in a synergistic anti-cancer effect. Kitov plans to explore higher doses and to test CM-24 in combination with an anti PD-1 inhibitor. A significant amount of data is available for the existing Investigational New Drug to support the continuation of the clinical studies. FameWave will enter into a joint clinical collaboration agreement, which is now in an advanced stage of negotiation with a major pharmaceutical company, for a planned Phase I/II study of CM-24 in combination with a PD-1 antibody in early 2020, with preliminary data expected in late 2020. As part of the agreement, three leading life science focused investment funds, Orbimed, Pontifax, and Arkin Holdings, who collectively hold approximately 90% of FameWave, will invest $3.5M in Kitov in exchange for newly issued ADSs of Kitov, priced at $1.23 per ADS. Following this investment and the FameWave share exchange transaction, Orbimed, Pontifax, and Arkin Holdings will each hold approximately 10% of Kitov's shares on a fully diluted basis. Kitov is also currently in discussions with a number of leading healthcare-focused institutional investors, which have expressed interest in investing in Kitov following completion of the acquisition. Kitov is acquiring 100% of FameWave from its shareholders in exchange for $10M worth of its newly issued ADSs with a long term lock-up period, priced at $1.23 per ADS, plus 50% warrant coverage based on an exercise price of $1.98 per ADS with a 4-year term. In addition, Kitov will provide a loan to FameWave of up to approximately $2M in to be paid to cCAM BioTherapeutics,which discovered CM-24, or to repay certain loans provided by FameWave's shareholders. In an initial Phase I dose ranging study of CM24 as single agent, no efficacy signals were detected and the decision was made to discontinue development, although such decision was not due to any known safety risks. MSD is therefore returning the rights to CM-24 to former cCAM shareholders and founders of FameWave. Based on a review of the Phase I study results by external scientific advisors retained by Kitov, coupled with their assessment that CM-24 was found to be generally safe, Kitov plans to explore higher doses in order to reach receptor saturation, and test CM-24 in combination with an anti PD-1 inhibitor in a well-defined patient population. The transaction has been approved by the boards of Kitov and FameWave and is expected to close during 3Q19, subject to: approval of Kitov shareholders; closing of the transaction for the return of CM-24 to FameWave by MSD; finalization by FameWave of the joint clinical collaboration agreement; and satisfaction of other customary closing conditions. Should the complete transaction not close, Kitov will be entitled to repayment of the amounts loaned by Kitov out of amounts actually received by FameWave from commercialization transactions of CM-24. If no such commercialization transaction is consummated within 36 months from termination, Kitov will be entitled to 20% of FameWave in return for the approximately $2M loan which was previously provided. Furthermore, should the transaction not close due to the failure of FameWave to finalize the clinical collaboration agreement, or the failure of certain other closing conditions to be fulfilled by the current shareholders of FameWave, then Kitov will be entitled to 100% of FameWave in return for the approximately $2M loan which was previously provided.

09:20 EDT Airgain appoints James Sims as CEO - Airgain announced the appointment of James Sims as CEO. Sims has served as Airgain's chairman of the board since November 2003 and interim CEO since May 2018. Prior to joining Airgain, Sims served as the founding partner of Silicon Valley Data Capital in 2017 and founded Silicon Valley Data Science in 2012, where he is currently the chairman. He currently serves on the board of various private companies including EPAY Systems.

09:10 EDT Mitsubishi UFJ member Union Bank extends Elavon alliance - Elavon and Union Bank have agreed to extend their multi-year alliance for the third time in their 25-year partnership, which adds a focus on expanding into vertical markets such as healthcare and enhancements to tools and services. Under the terms of the agreement, Union Bank's new and existing merchant customers will benefit from Elavon's investment in new payment technologies and tools and services.

09:06 EDT SCE questions investigation report on 2017 Thomas Fire - Southern California Edison issued last night the following response to the report by CAL FIRE and VCFD on their review of the causes of the Anlauf Canyon ignition of the Thomas Fire: "We keep in our thoughts all those who have been affected by wildfires. The devastating loss of lives, homes and businesses is tragic, and SCE will continue to provide assistance and support to those affected by wildfires. The safety of our customers, our employees and our communities remains our most important focus. SCE believes evidence shows there were at least two separate ignitions on Dec. 4, 2017, that led to two fires that together are commonly referred to as the Thomas Fire - one in the Anlauf Canyon area of Ventura County and another near Koenigstein Road in the city of Santa Paula. Based on currently available information, SCE has not determined whether its equipment caused the ignition in the Anlauf Canyon area. SCE has evidence that the ignition at Anlauf Canyon started at least 12 minutes prior to any issue involving SCE's system and at least 15 minutes prior to the start time indicated by VCFD in its report. SCE provided this evidence to CAL FIRE and VCFD investigators; however, the report does not suggest this evidence was considered. SCE believes the Anlauf Canyon ignition may have been independently responsible for a significant portion of the Thomas Fire damages. SCE also is not aware of any basis for criminal liability. Separately, the company previously disclosed that its equipment appears to have been associated with the Koenigstein ignition. The specific cause cannot be determined until SCE can analyze the equipment currently in CAL FIRE's possession and any other evidence that may be described in a separate report, relating to the Koenigstein ignition, which has not yet been issued. SCE fully cooperated with fire officials throughout their investigation."

08:57 EDT General Electric expects FY19 to be a 'reset year' with Q1 as weakest quarter - GE expects FY19 to be a "reset year" with Q1 as the weakest quarter. GE sees "meaningful improvement, industrial free cash flow positive in 2020/2021. Management says Power turnaround will not be "quick." Sees 'significant improvements' to Power over the long-term. Management said, "We understand how we got here and know how to fix this." Comments provided during 2019 GE Investor Outlook conference call.

08:48 EDT Charles Schwab reports February core net new assets $18.3B - The Charles Schwab Corporation released its Monthly Activity Report. Company highlights for the month of February 2019 include: Core net new assets brought to the company by new and existing clients in February 2019 totaled $18.3B. Net new assets excluding mutual fund clearing totaled $17.2B. Total client assets were $3.53T as of month-end February, up 6% from February 2018 and up 2% compared to January 2019. Active brokerage accounts were 11.7 million as of month-end February, up 7% from February 2018 and up 1% from January 2019.

08:46 EDT SilverCrest Metals Inc trading halted, news pending

08:41 EDT Atossa Genetics gets FDA 'Safe to Proceed' letter for patient use of Endoxifen - Atossa Genetics announced that the FDA has issued a "Safe to Proceed" letter under their "expanded access" program permitting the use of Atossa's oral Endoxifen as a post-mastectomy treatment in a pre-menopausal, estrogen-receptor positive, or ER+, breast cancer patient. This patient completed a 3-week course of Atossa's oral Endoxifen prior to her surgery under an FDA-approved expanded access program. The tumor activity from the initial biopsy was compared to the tumor activity at surgery, finding that the cancer cell biological activity was reduced by two measures: the Ki-67 activity decreased by 50% and the estrogen receptor content decreased by over 20%. There were no safety or tolerability issues, including vasomotor symptoms such as hot flashes and night sweats. The latter symptoms are often a tolerability challenge for patients on tamoxifen. The importance of Ki-67 as a marker of estrogen-receptor breast cancer cell activity has evolved over the past few years. In a 2017 peer-reviewed paper in which a meta-analysis was conducted and included 49 studies and 14,046 patients, five studies reported and compared the change of Ki-67 following pre-surgery hormonal therapy treatment and the disease-free survival, or DFS. The authors reported that from their analysis, a Ki-67 change that is either low or none, as well as an increase, is associated with worse DFS. The reduction of Ki-67 in the tumor of the patient who received oral Endoxifen prior to her mastectomy is considered large, based on the criteria of this paper. Under the FDA expanded access IND program, the use of Atossa's proprietary oral Endoxifen is restricted solely to this patient. Approval from the Institutional Review Board must be obtained prior to providing oral Endoxifen to this patient.

08:39 EDT Tesla appoints Zachary Kirkhorn as CFO to succeed Deepak Ahuja - In a regulatory filing, Tesla reported that it has appointed Zachary Kirkhorn as its Chief Financial Officer to succeed Deepak Ahuja. "Kirkhorn first joined Tesla in March 2010 and has continuously served in various roles in its finance department other than a two-year period between 2011 and 2013 during which he obtained his M.B.A. from Harvard Business School, including most recently as Vice President, Finance, Financial Planning and Business Operations since December 2018," the company stated. Also on March 13, Tesla appointed Vaibhav Taneja, Tesla's current Corporate Controller since May 2018, as its Chief Accounting Officer.

08:21 EDT Myriad Genetics myPath Melanoma test receives Medicare coverage - Myriad Genetics announced that the Medicare administrative contractor Palmetto GBA MolDx has issued a final local coverage determination for the myPath Melanoma test to help physicians provide a definitive diagnosis when a suspicious skin lesion is equivocal based upon histopathology. The myPath Melanoma test analyzes 23 genes and has proven to be highly accurate in multiple studies at distinguishing melanoma from benign moles.

08:18 EDT Chaparral Energy sees Q1 average daily production 20.5-21.5 mboepd - Sees Q1 STACK average daily production 15.5-16.5 mboepd.

08:09 EDT Integra LifeSciences announces approval of DuraGen in Japan - Integra LifeSciences announced the recent approval of DuraGen Dural Regeneration Matrix in Japan. DuraGen is the first and only non-autologous collagen xenograft approved for use as a dural substitute in Japan.

08:05 EDT Stryker completes $110M acquisition of OrthoSpace - Stryker announced it has completed the acquisition of OrthoSpace in an all cash transaction for an upfront payment of $110M and future milestone payments of up to an additional $110M. OrthoSpace's product portfolio provides a differentiated technology for the treatment of massive irreparable rotator cuff tears. The InSpace product is a biodegradable sub-acromial spacer, which is designed to realign the natural biomechanics of the shoulder. The technology has a long clinical history with over 20,000 patients treated across 30 countries. In the U.S., InSpace is currently under clinical study and not approved for use. The transaction is expected to have an immaterial impact to net earnings.

07:47 EDT Allegheny Technologies STAL joint venture commissions new line - Allegheny Technologies commissioned STAL 3, the latest expansion of its 20-year STAL joint venture to produce precision stainless steel strip for China and the Asian markets. STAL 3 increases capacity by approximately 65%. The expansion includes a 1219 mm wide Cold Rolling Mill enabling production of sheets thinner than a human hair, a bright anneal line and associated auxiliary finishing equipment.

07:38 EDT State Street company Charles River Development partners with Axioma - State Street Corporation announced that Charles River Development and Axioma announced a formalized strategic partnership. The partnership will integrate Axioma's risk and portfolio analytics into the Charles River Investment Management Solution, a front and middle office platform used by more than 300 investment managers, asset owners and hedge funds globally. As a result, Charles River clients will benefit from access to Axioma's full suite of factor models and portfolio optimization capabilities directly within the Charles River IMS.

07:34 EDT Biohaven initiates enrollment in Phase 3 clinical trial of troriluzole - Biohaven Pharmaceutical has enrolled the first patient in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in Spinocerebellar Ataxia, or SCA. Hereditary Spinocerebellar Ataxias are rare, potentially fatal neurodegenerative disorders affecting the cerebellum. Currently, there are no FDA-approved treatments and there is no cure for SCA. Biohaven expects to enroll approximately 230 patients in this trial across approximately 22 sites in the United States. Researchers will evaluate the efficacy and safety of troriluzole over 48 weeks in patients with a diagnosis of SCA Types 1, 2, 3, 6, 7, 8, and 10. The primary outcome measure is the change in a patient's score on the Modified Functional Scale for the Assessment and Rating of Ataxia.

07:13 EDT Dollar General down 4.7% to $115 after Q4 results, FY19 guidance miss estimates

07:11 EDT McDermott announces startup of largest CDAlky reactor to date in China - McDermott announced the commercialization and startup of its single largest CDAlky reactor to date at PetroChina's refinery in Jilin, China. The 350,000 metric ton per annum, or 9,000 barrels per day, plant is one of four CDAlky projects awarded to the company by PetroChina, with startup occurring just 17 months after initial design.

07:08 EDT Anixa Biosciences granted additional cancer detection technology patent - Anixa Biosciences has been issued a Notice of Allowance by the USPTO for an additional cancer detection technology patent. This patent provides broader coverage for the use of Anixa's technology in a wider range of applications and protects critical new improvements developed for Anixa's cancer detection technology. This patented technology is a key component of Cchek, Anixa's early cancer detection platform.

07:07 EDT General Electric sees adjusted Industrial free cash flows to be positive in 2020 - General Electric said: "Looking ahead to 2020 and 2021, GE expects adjusted Industrial free cash flows to be positive in 2020, with the pace of improvement accelerating in 2021. The company remains committed to its financial policy of targeting a rating in the Single A range, an Industrial leverage ratio of less than 2.5X net debt to EBITDA, and a GE Capital debt-to-equity ratio of less than 4x."

07:04 EDT Bruker acquires Arxspan, terms not disclosed - Bruker announced that it has acquired Arxspan, a provider of cloud-based scientific software and workflow solutions, based in Southborough, Massachusetts. Arxspan is known for its line of cloud-based products for the management of research data under the Arxlab brand. The company has a focus on serving pharmaceutical and biopharma customers. Financial details of the transaction were not disclosed.

07:03 EDT Jury finds in favor of Whirlpool in water filter deception case - A jury returned its verdict in Whirlpool's favor, finding that FiltersFast's marketing practices were willful and were likely to deceive consumers. The jury also awarded Whirlpool $5.8M. FiltersFast was prominently and deceptively referencing Whirlpool's brands and using images of genuine Whirlpool products to sell non-genuine, third-party branded water filters. These filters did not meet Whirlpool's high quality standards and were not certified to remove as many contaminants as genuine Whirlpool filters.

07:00 EDT Becton Dickinson receives FDA approval for Venovo venous stent - BD announced the FDA has granted premarket approval for the Venovo venous stent, the first stent indicated to treat iliofemoral venous occlusive disease, which is obstructed or narrowed blood flow specific to the iliac and femoral veins located near the groin. The Venovo venous stent is a flexible nitinol stent specifically designed to reopen blocked iliac and femoral veins in order to maintain adequate blood flow. The Venovo venous stent is designed with a balance of radial strength, compression resistance and flexibility needed for the treatment of symptomatic post-thrombotic and non-thrombotic iliofemoral lesions. Additionally, the broad stent sizing allows clinicians to treat large diameter veins and long lesion lengths.

06:59 EDT Dollar General raises quarterly dividend 10% to 32c per share - The dividend is payable on or before April 23 to shareholders of record on April 9.

06:57 EDT Dollar General sees FY19 share repurchases approximately $1B

06:50 EDT Merck's Keytruda combination in NSCLC approved by European Commission - Merck's Keytruda, the company's anti-PD-1 therapy, has been approved by the European Commission in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of adults with metastatic squamous non-small cell lung cancer or NSCLC. This approval is based on data from the Phase 3 Keynote-407 trial, which demonstrated that Keytruda in combination with chemotherapy significantly improved overall survival in adults with metastatic squamous NSCLC regardless of PD-L1 tumor expression status, reducing the risk of death by 36% compared to chemotherapy alone. The approval allows marketing of the Keytruda combination in all 28 EU member states plus Iceland, Lichtenstein and Norway, at the approved dose of 200 mg every three weeks until disease progression or unacceptable toxicity.

06:47 EDT Infineon names Sven Schneider CFO - The Supervisory Board of Infineon Technologies (IFNNY) has appointed Dr. Sven Schneider to become the CFO effective 1 May 2019. His contract will initially run for three years. Dr. Schneider is moving to Infineon from Linde (LIN), where he is currently Board Spokesman, CFO and Labor Director. Schneider succeeds Dominik Asam, who will be moving to Airbus (EADSY) on 1 April. During the one-month transition period, Infineon Technologies CEO Reinhard Ploss will manage the company's finance organization. As CFO, Schneider will be in charge of Accounting & Reporting, Financial Controlling, Financial Planning, Investor Relations, Taxes, Treasury, Auditing, Compliance, Export Control, Risk Management, Business Continuity, and Information Technology.

06:42 EDT Scorpio Bulkers signs sale and leaseback agreements for seven dry bulk vessels - Scorpio Bulkers has agreed to sell and leaseback three Ultramax vessels and four Kamsarmax vessels to CMB Financial Leasing. Upon completion, which is estimated to take place in Q2, the company's liquidity is expected to increase by $57.2M in aggregate, comprising $45.4M upon closing after the repayment of outstanding debt and an additional tranche of up to $11.8M for installation of exhaust gas cleaning systems on the seven vessels. As part of the agreements, the company will bareboat charter-in the vessels for a period of seven years. In addition, the company has purchase options beginning after the end of the third year of each agreement. There is also a purchase option for each vessel upon the expiration of each agreement.

06:13 EDT EyePoint sees cash and cash equivalents sufficient through remainder of 2019

06:08 EDT CAE says Bombardier BAT acquisition to provide high single-digit EPS accretion - CAE (CAE) confirmed that it has concluded the previously announced acquisition of Bombardier's (BDRBF) Business Aircraft Training business for an enterprise value of $645M. All the required conditions for closing have been met. The acquisition, which was first announced on November 8, 2018, is expected to provide high single-digit EPS accretion for CAE within its first full year and to be free cash flow accretive as well.

06:06 EDT Embraer reports Q4 adj. EPS (4c), consensus (2c) - Reports Q4 revenue $1.67B, consensus $1.69B. Embraer delivered 33 commercial jets and 36 executive jets in Q4. The company's firm order backlog increased to $16.3B at the end of Q4, including contracts of the Services & Support segment, up from the $13.6B reported at the end of Q3.

06:04 EDT Sprague Resources sees 2019 adjusted EBITDA $105M-$125M vs. $102.0M in 2018 - Sees 2019 quarterly distributions at current level.

05:49 EDT Align Technology announces strategic alliance with Digital Smile Design - Align Technology announced that it is partnering with Digital Smile Design, or DSD. Through the collaboration, DSD will highlight the Invisalign system and iTero Element scanners as the digital solutions of choice for tooth movement and scanning. As part of the cooperation, Align and DSD will aim to deliver dedicated education programs, enable simplified, streamlined integration of digital end-to-end workflows into GP practice and offer doctors more opportunities to learn about digital tools and treatment planning support.

05:36 EDT Roche announces EC approval of Hemlibra - Roche announced that the European Commission has approved Hemlibra for routine prophylaxis of bleeding episodes in people with severe haemophilia A without factor VIII inhibitors. Hemlibra can be used in all age groups, and can also now be used at multiple dosing options for all indicated people with haemophilia A, including those with factor VIII inhibitors. This approval is based on results from the pivotal HAVEN 3 and HAVEN 4 studies. In the HAVEN 3 study in people with haemophilia A without factor VIII inhibitors, Hemlibra prophylaxis led to statistically significant and clinically meaningful reductions in treated bleeds compared to no prophylaxis, and compared to prior treatment with factor VIII prophylaxis in a prospective intra-patient comparison. In the HAVEN 4 study in people with haemophilia A with and without factor VIII inhibitors, Hemlibra showed a clinically meaningful control of bleeding when dosed every four weeks.

05:25 EDT Facebook says cooperating with ongoing federal investigations - In response to the New York Times report that U.S. federal prosecutors are conducting a criminal investigation into data deals Facebook struck with some of large tech companies, Facebook said via Twitter, "It's already been reported that there are ongoing federal investigations, incl. by the Dept of Justice. As we've said, we're cooperating w/ investigators and take those probes seriously. We've provided public testimony, answered questions, and pledged that we'll continue to do so."